S. 2157 · 115th Congress
Drug-Price Transparency in Communications Act
- Stage
- In committee
- Sponsor
- Richard Durbin
- Introduced
- 2017-11-16
- Latest action
- 2017-11-16 · Introduced in Senate
Summary
Drug-Price Transparency in Communications Act
This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.
The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.